Treatment with recombinant PTX3 reduced P. aeruginosa colonization in cystic fibrosis mice and synergized with antifungals in the therapy of A. fumigatus infections (15, 18, 28, 46), paving the way for the development of PTX3 as potential new therapeutic molecule in these opportunistic infections. Here, PTX3 is linked to cystic fibrosis.